CA2392568A1 - Procede de prevention et/ou de traitement de l'atherosclerose - Google Patents

Procede de prevention et/ou de traitement de l'atherosclerose Download PDF

Info

Publication number
CA2392568A1
CA2392568A1 CA002392568A CA2392568A CA2392568A1 CA 2392568 A1 CA2392568 A1 CA 2392568A1 CA 002392568 A CA002392568 A CA 002392568A CA 2392568 A CA2392568 A CA 2392568A CA 2392568 A1 CA2392568 A1 CA 2392568A1
Authority
CA
Canada
Prior art keywords
lxr
ligand
receptor
patient
ppar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002392568A
Other languages
English (en)
Inventor
Carl P. Sparrow
John G. Ondeyka
Sheo Bux Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2392568A1 publication Critical patent/CA2392568A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé d'élévation des taux sériques de cholestérol HDL, consistant à administrer une dose efficace sur le plan thérapeutique d'un ligand LXR à un patient nécessitant un tel traitement. L'invention concerne en outre un procédé d'utilisation d'un ligand LXR aux fins de stimulation de l'expression du gène ABC1. On peut utiliser des ligands LXR pour prévenir et traiter l'athérosclérose et des états associés.
CA002392568A 1999-12-13 2000-12-07 Procede de prevention et/ou de traitement de l'atherosclerose Abandoned CA2392568A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17040399P 1999-12-13 1999-12-13
US60/170,403 1999-12-13
PCT/US2000/033098 WO2001041704A2 (fr) 1999-12-13 2000-12-07 Procede de prevention et/ou de traitement de l'atherosclerose

Publications (1)

Publication Number Publication Date
CA2392568A1 true CA2392568A1 (fr) 2001-06-14

Family

ID=22619728

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002392568A Abandoned CA2392568A1 (fr) 1999-12-13 2000-12-07 Procede de prevention et/ou de traitement de l'atherosclerose

Country Status (5)

Country Link
EP (1) EP1239855A4 (fr)
JP (1) JP2003516327A (fr)
AU (1) AU2064701A (fr)
CA (1) CA2392568A1 (fr)
WO (1) WO2001041704A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617122B1 (en) 1999-03-15 2003-09-09 Xenon Genetics, Inc. Process for identifying modulators of ABC1 activity
EP1854880A1 (fr) * 1999-03-15 2007-11-14 University of British Columbia Procédés et réactifs pour moduler les niveaux de cholestérol
US6835563B1 (en) 1999-06-18 2004-12-28 Cv Therapeutics Compositions and methods for increasing cholesterol efflux and raising HDL ATP binding cassette transporter protein ABC1
US6821774B1 (en) 1999-06-18 2004-11-23 Cv Therapeutics, Inc. Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter ABC1
WO2001015676A2 (fr) * 1999-09-01 2001-03-08 University Of British Columbia Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides
EP1203588A1 (fr) * 2000-11-06 2002-05-08 Bayer Ag Régulation stérol-indépendante du promoteur ABC1 par l' oncostatineM
US6908934B2 (en) * 2001-06-11 2005-06-21 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
WO2003031408A2 (fr) * 2001-10-08 2003-04-17 Eli Lilly And Company Composes tricycliques utiles pour moduler lxr
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
GB2381866A (en) * 2001-11-12 2003-05-14 Karobio Ab Assays for liver X receptor (LXR) modulators
AU2003220521A1 (en) * 2002-03-27 2003-10-13 Smithkline Beecham Corporation Methods of treatment with lxr modulators
WO2004011448A1 (fr) 2002-07-25 2004-02-05 Merck & Co., Inc. Composes therapeutiques destines au traitement d'etats dyslipidemiques
WO2004050598A1 (fr) * 2002-12-03 2004-06-17 Kowa Co., Ltd. Procede pour preparer de l'anhydride acetylpodocarpique
PE20050676A1 (es) * 2003-12-12 2005-11-02 Wyeth Corp Quinolinas referidas a enfermedades cardiovasculares
KR101021828B1 (ko) 2004-10-27 2011-03-17 다이이찌 산쿄 가부시키가이샤 2 이상의 치환기를 갖는 벤젠 화합물
AU2006245717B8 (en) 2005-05-10 2010-10-14 Laboratoires Fournier S.A. Novel use of liver X receptor agonists
US10583102B2 (en) 2014-10-06 2020-03-10 The Johns Hopkins University Targeting liver nuclear receptors as a treatment for wilson disease
AU2018269568B2 (en) * 2017-05-18 2022-03-24 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
SG11202105175WA (en) 2018-11-20 2021-06-29 Regeneron Pharma Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists
EP3887401A2 (fr) 2018-11-26 2021-10-06 Denali Therapeutics Inc. Procédés de traitement du métabolisme lipidique dérégulé

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
ATE236137T1 (de) * 1996-02-02 2003-04-15 Merck & Co Inc Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
WO2003053352A2 (fr) * 2001-12-20 2003-07-03 Merck & Co., Inc. Composes therapeutiques destines au traitement d'etats dyslipidemiques

Also Published As

Publication number Publication date
AU2064701A (en) 2001-06-18
JP2003516327A (ja) 2003-05-13
WO2001041704A3 (fr) 2001-12-06
EP1239855A2 (fr) 2002-09-18
WO2001041704A2 (fr) 2001-06-14
EP1239855A4 (fr) 2004-04-21

Similar Documents

Publication Publication Date Title
AU2064701A (en) Method for the prevention and/or treatment of atherosclerosis
ES2320181T3 (es) Composiciones farmaceuticas que tienen un efecto reductor del colesterol.
US7060733B2 (en) Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species
US10343985B2 (en) Cryopyrin inhibitors for preventing and treating inflammation
JP2003525217A (ja) 肥満治療用薬剤
US8269034B2 (en) C-nitroso-derived nitroxyl donors
US20030086923A1 (en) Method for the prevention and/or treatment of atherosclerosis
BG104432A (bg) Терапевтично използване на хинолинови производни
JPWO1999004815A1 (ja) コレステロール低下作用を有する医薬組成物
AU2019257632A1 (en) Use of neutrophil elastase inhibitors in liver disease
CN105753817A (zh) 一类取代氮杂环衍生物及其应用
KR20020010581A (ko) 핵수용체 ｐｐａｒ의 신규한 리간드
McChesney et al. Metabolism of chloroquine and hydroxychloroquine in albino and pigmented rats
US20030125357A1 (en) Therapeutic compounds for treating dyslipidemic conditions
EP3999045A1 (fr) Composés en tant qu'inhibiteurs d'inflammasome de nlrp3 et compositions et utilisations de ceux-ci
KR20030040225A (ko) 씨오엠티 저해효과를 가지는 쿠마린 유도체
CN114315754A (zh) 一种异羟肟酸类化合物及其用途
JP2514163B2 (ja) ピリミドン誘導体及び類似化合物を含有する、喘息又は炎症性気道疾患の治療用医薬組成物
US20220184172A1 (en) Ampk/caspase-6 axis controls liver damage in nonalcoholic steatohepatitis
EP2045246A1 (fr) Dérivés de benzo[d] isothiazoles utilisés comme inhibiteurs des histone-désacétylases
US5149688A (en) Methods, compounds, and compositions for immunosuppression
US7081260B2 (en) α-Glucosidase inhibitors from a natural source
US6525098B1 (en) 6-methoxy-2-naphthylacetic acid prodrugs
CN106974899A (zh) 抗凝血化合物及其用途
JP2005519042A (ja) 異脂肪血症状態を治療するための治療用化合物

Legal Events

Date Code Title Description
FZDC Correction of dead application (reinstatement)
FZDE Dead